Navigation Links
OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
Date:5/30/2009

and Hsp-27 positive CTC counts, coupled with decreases in serum PSA and CA-125 levels in patients with prostate and ovarian cancer, markers that strongly suggest single agent anti-cancer activity for OGX-427," said Dr. Sebastien Hotte, Principal Investigator and a medical oncologist at Juravinski Cancer Centre, Hamilton, Ontario.

"We are very satisfied with the safety profile of OGX-427 to date in this trial and the early, strong indicators of anti-tumor and biological activity," said Scott Cormack, president and CEO of OncoGenex Pharmaceuticals.

About OGX-427

OGX-427 is designed to reduce production of Hsp27, a protein that is over-produced in response to many cancer treatments including hormone ablation therapy, chemotherapy and radiation therapy. Hsp27 production has been shown to inhibit cell death in tumor cells through a variety of mechanisms. OGX-427 is being evaluated in a Phase 1 clinical trial for the treatment of solid tumors including prostate, non-small cell lung, breast, ovarian, and bladder cancers. Like OGX-011, this product candidate has potential as a treatment in a broad number of cancers.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisen
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
2. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
3. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
4. OncoGenex Reports First Quarter Financial Results
5. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
6. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
7. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
8. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
9. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
10. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
11. OncoGenex To Present At The RBC Capital Markets 2008 Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... PHILADELPHIA , Nov. 26, 2014 /PRNewswire-USNewswire/ ... unforgiving environments. Human exploration of space requires astronauts to ... mission safety and success, and prevent potential errors and ... success, little is known about how cognition is affected ... primarily affected. Now, Penn Medicine researchers are ...
(Date:11/26/2014)... On January, 14, 2015, UMBC’s Biotechnology ... science community to the UMBC campus for a discussion ... Protein Society, will take place from 9 a.m. to ... Through discussion, presentations and workshops, the free symposium will ... role in the industry and the future of protein ...
(Date:11/26/2014)... PMG Research, Inc. announced today the formation ... of sites that provide clinical research services to pharmaceutical companies ... through its partnerships with large physician practices and integrated health ... in the Southeastern United States and spans over 60 physician ... will be held by: Dr. Robert Holmes, MD, of ...
(Date:11/26/2014)... NC (PRWEB) November 25, 2014 ... Intensity Focused Ultrasound (HIFU) devices, recently participated in ... Small Renal Mass 360° .” Key opinion leaders ... therapeutic advances related to small renal masses while ... about different ablative technologies in hands-on labs. Attendees ...
Breaking Biology Technology:Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 2Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 3Penn Medicine Team Develops Cognitive Test Battery to Assess the Impact of Long Duration Spaceflights on Astronauts' Brain Function 4PMG Research Names Medical Advisory Board 2PMG Research Names Medical Advisory Board 3SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 2SonaCare Medical Supports American Urology Association’s Small Renal Mass 360° Summit 3
... 15, 2011 This evening, Novo Nordisk awarded sponsorships ... support programs that educate people living with type 2 ... reduce the risk of long-term diabetes related complications. The ... program – a new initiative that aims to promote ...
... 15, 2011 Roka Bioscience announced today that the ... certification of the Listeria Detection Assay. This evaluation is ... (AOAC-RI) certification of methods used in the food safety ... laboratory and monitored by AOAC. The internal portion of ...
... /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... pharmaceutical and biotechnology research and development outsourcing company, ... leading Chinese pharmaceutical company, today announced that Shanghai ... and Hengrui have entered into a strategic partnership ...
Cached Biology Technology:Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 2Novo Nordisk and Atlanta Area Organizations Partner on Diabetes Education Programs 3Roka Bioscience Initiates External Trial for AOAC Certification 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 2ShangPharma Subsidiary and Jiangsu Hengrui Medicine Partner in Therapeutic Antibody Research and Development 3
(Date:11/3/2014)... Cancer Center study published in this month,s ... describes the activity of a recently discovered communication molecule ... It has been known to limit inflammation and the ... system: IL-37 inhibits the ability of the immune system ... mechanism that underlies IL-37,s effect on the immune system ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
(Date:11/2/2014)... of a bold quest to rid the world entirely ... announced an award of US$156 million to PATH to ... new vaccines that will interrupt the cycle of malaria ... agenda. Such vaccines would ensure that parasite reintroduction is ... bed net." , This approach to developing malaria ...
Breaking Biology News(10 mins):PNAS: From HIV to cancer, IL-37 regulates immune system 2Preterm, low birth-weight babies may need new hips in adulthood 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... therapy (ECT) is the most effective acute treatment for ... ECT, there remains a significant risk of adverse cognitive ... that the regions that need to be stimulated to ... from the regions that result in memory problems (the ...
... study led by researchers from Harvard School of Public ... the UK has, for the first time, used genome ... population following the introduction of a vaccine. The study ... the introduction of the ,Prevnar, conjugate polysaccharide vaccine, which ...
... University of Manchester scientists, writing in the journal Nature ... can both have an unexpected cooling effect on the world,s ... water droplets, condensed on to tiny particles suspended in the ... into cloud droplets. It has been known for some decades ...
Cached Biology News:Researchers reveal new more precise method of performing electroconvulsive therapy 2Genome sequencing provides unprecedented insight into causes of pneumococcal disease 2Organic vapors affect clouds leading to previously unidentified climate cooling 2
Immunogen: Extract of pigmented melanoma metastases from lymph nodes. Storage: -20 C, Avoid Freeze/Thaw Cycles...
with GlutaMAXIL-glutamine...
alpha N-catenin (C-19)...
This STAT antibody sampler pack contains 8 monoclonal ,STAT antibodies....
Biology Products: